Salute e Benessere

Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST…

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 7 August 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility…
Nasdaq GlobeNewswire
07/08/2025

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust…

Leuven, België, 7 augustus 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutische vennootschap gevestigd in Leuven, kondigt vandaag de definitieve stopzetting aan van zijn preklinisch onderzoeksprogramma gericht op de ontwikkeling van nieuwe therapeutische doelwitten voor geografische maculaire degeneratie (GA)…
Actusnews Wire
07/08/2025

Oxurion Ends RD Program in Geographic Atrophy and Refocuses on New CRO…

Leuven, BELGIUM – August 7, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced the definitive termination of its preclinical research program aimed at developing new therapeutic targets for geographic atrophy (GA). This program relied on a high-throughput genetic…
Actusnews Wire
07/08/2025

SurgiBox Achieves CE Mark for SurgiField System Devices to Improve Access to…

CE Certification positions SurgiBox for global expansion and robust sales acceleration SurgiBox, a medical technology company committed to improving access to safe, clean surgery at the point of need, announced today it has received the CE Mark under MDR for the medical devices that comprise its flagship product, the SurgiField™ System. The CE Mark under the European Union’s Medical Device Regulation (MDR 2017/745) standards certifies compliance with stringent health, safety, and...
Nasdaq GlobeNewswire
07/08/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
Nasdaq GlobeNewswire
07/08/2025

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025 Copenhagen, Denmark;Interim Report for the First Half Ended June 30, 2025Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts...
Nasdaq GlobeNewswire
07/08/2025

Autoimmunity Diagnostics Market worth US$8.98 billion by 2031 with 8.3% CAGR |…

Browse in-depth TOC on "Autoimmunity Diagnostics Market" Browse in-depth TOC on "Autoimmunity Diagnostics Market" 312 - Tables 57- Figures 296 - Pages By product,the autoimmunity diagnostics market is divided into two segments: consumables and instruments. The consumables segment accounted for the highest CAGR over the forecast period, which was led by the continuous need for consumables for various diagnostic tests. This growth is driven by the increasing frequency of...
PR Newswire
07/08/2025

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints…

Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R 2 ) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value <0.0001) versus R 2alone in patients with relapsed/refractory (R/R) Follicular Lymphoma (FL) Results from EPCORE FL-1 form the basis of global regulatory submissionsU.S. FDA has accepted for...
Nasdaq GlobeNewswire
07/08/2025

Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3…

This robust growth trajectory reflects the increasing adoption of BCI technologies across healthcare, consumer electronics, and military applications. The expanding demand for non-invasive BCI systems, advancements in neural signal processing, and integration with AI are key factors contributing to the market's rapid expansion and scalability. This robust growth trajectory reflects the increasing adoption of BCI technologies across healthcare, consumer electronics, and military applications...
PR Newswire
07/08/2025

Boehringer and Click Therapeutics’ investigational prescription digital…

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP.CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial. 1,2 Often underappreciated and less recognized, negative symptoms impact more than half of people living with schizophrenia. 3 Ingelheim, Germany /...
Nasdaq GlobeNewswire
07/08/2025

Update Hydrolyzed Collagen Market Forecast at CAGR 5.5% Through 2031: Highlight…

The demand for functional foods and dietary supplements has particularly increased among older people. Hydrolyzed collagen is widely recognized for its benefits and skin health, joint support, and overall vitality, which results in its use in functional food and dietary supplement formulations. Additionally, the growing popularity of clean-label and protein-rich products is prompting manufacturers to incorporate hydrolyzed collagen as a premium ingredient in edible and topical formulations…
PR Newswire
07/08/2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES…

The DEWS III report, which appears in the June 2025 issue of American Journal of Ophthalmology, cites two studies of Nordic Pharma's novel crosslinked hyaluronic acid (HA) canalicular filler in Section 6.2.4 Newer Plug Designs and Other Technologies. The first study found improvements in corneal staining, Schirmer test scores and other measurements three months after administration. A second study, comparing LACRIFILL Canalicular Gel with a commercially available hydrogel canalicular plug, found…
PR Newswire
07/08/2025

ALMORA BOTANICA GRANTED TWO GROUNDBREAKING PATENTS

The patents validate Almora Botanica's mission to modernise traditional Ayurvedic formulations through advanced science and clinically proven results; delivering high-performance, natural skincare without compromise. The patents validateAlmora Botanica'smission to modernise traditional Ayurvedic formulations through advanced science and clinically proven results; delivering high-performance, natural skincare without compromise. Two patents, one vision for the future of Ayurveda: ...
PR Newswire
07/08/2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate…

VERO BEACH, Fla., Aug.07, 2025(GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA),a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.We believe that strategic engagement with emerging financial technologies, including select...
Nasdaq GlobeNewswire
07/08/2025

Implantica presents the second quarter 2025 on August 14 at 15:00 CEST

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica...
PR Newswire
07/08/2025

ZINZINO AB (PUBL): Share subscription due to warrants

The total number of B shares increased by 100,950 to 31,170,664. The total number of shares after the increase was 36,252,567. The dilution amounted to 0.28 percent. Zinzino's share capital increased to SEK 3,625,256.70. The total number of B shares increased by 100,950 to 31,170,664. The total number of shares after the increase was 36,252,567. The dilution amounted to 0.28 percent. Zinzino's share capital increased toSEK 3,625,256.70. For more information:Dag Bergheim Pettersen CEO...
PR Newswire
07/08/2025

IBA Notice of Half Year 2025 Results and Conference Call

HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2025 onThursday, 28 August 2025 at 7am CEST.Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present...
Nasdaq GlobeNewswire
07/08/2025

Implantica announces second publication of groundbreaking 5-year results from…

The second publication, titled "Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: A prospective multicenter trial of safety and effectiveness," provides the ultimate validation of RefluxStop®'s consistent and outstanding clinical performance. Key highlights include: The second publication, titled"Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: A prospective multicenter trial of safety and…
PR Newswire
07/08/2025

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine…

Saint Herblain (France), August 7, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ ®in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ ®. IXCHIQ ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at...
Nasdaq GlobeNewswire
07/08/2025

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEBasel, August 7, 2025 –Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR % [2] ...
Nasdaq GlobeNewswire
07/08/2025

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global…

With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe…
PR Newswire
07/08/2025

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034)…

Key Takeaways from the Urothelial Carcinoma Market Report Key Takeaways from the Urothelial Carcinoma Market Report Discover the urothelial carcinoma new treatment @New Treatments for Urothelial Carcinoma Urothelial Carcinoma Market Dynamics The urothelial carcinoma market dynamics are expected to change in the coming years.Advancements in computational and bioinformatics platforms, along with various R&D practices, are enabling the development of the urothelial...
PR Newswire
06/08/2025

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and…

Key Takeaways from the CLK Inhibitors Market Report Key Takeaways from the CLK Inhibitors Market Report Discover which indication is expected to grab the major CLK inhibitors market share @CLK Inhibitors Market Report CLK Inhibitors Market Dynamics The CLK inhibitors market is gaining attention due to therising interest in alternative splicingas a therapeutic target. CLKs, particularly CLK1-4, regulate thephosphorylation of serine/arginine-rich (SR) proteins, which...
PR Newswire
06/08/2025

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial…

CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid…
PR Newswire
06/08/2025
Altri  Comunicati